DISCLAIMER: FOR EDUCATIONAL PURPOSES ONLY. CONSULT A HEALTHCARE PROFESSIONAL BEFORE ADMINISTERING ANY MEDICATION.
Peptides+ Chart

Retatrutide Reconstitution & Dosage Calculator

Calculate Retatrutide reconstitution and weekly dosing. Triple agonist (GLP-1/GIP/Glucagon) peptide calculator with titration schedule.

Retatrutide

Calculate Retatrutide reconstitution and weekly dosing. Triple agonist (GLP-1/GIP/Glucagon) peptide calculator with titration schedule.

mL

For research purposes only. Retatrutide is an investigational compound not approved for human use. Always work with qualified professionals.

Visual Syringe Guide

Use this interactive syringe visualization to verify your calculated dose. Enter the volume from your calculation above to see exactly where the plunger should land.

Syringe Configuration

mL
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Administration Note

For a 0.50 mL dose, pull the plunger back until the top ring of the black stopper aligns with the corresponding mark.

Volume Match0.50 mL

Important Disclaimer

For research purposes only. Retatrutide is an investigational compound not approved for human use. Always work with qualified professionals.

About This Calculator

Retatrutide is a novel triple agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. This calculator helps researchers determine precise reconstitution ratios and dosing volumes.

How It Works

Enter your vial size, the amount of bacteriostatic water for reconstitution, and select your target weekly dose based on your titration phase. The calculator provides the exact volume needed per injection.

Frequently Asked Questions

Retatrutide is a triple agonist (GLP-1/GIP/Glucagon) while Semaglutide is a single GLP-1 agonist. The additional receptor activity may provide enhanced metabolic effects in research settings.
Clinical Review
Dr. Igor I. Bussel
Dr. Igor I. Bussel, MD
Board-Certified Ophthalmologist

Dr. Igor I. Bussel is a board-certified ophthalmologist and fellowship-trained surgeon affiliated with the University of California, Irvine (UCI), the Gavin Herbert Eye Institute, and the UCI School of Medicine.

Last Updated: 2026-01-06
Medically Reviewed
Evidence-Based
Updated 2026-01-06